Back to search

Article

Anti-VEGF vascular remodeling drives germinal center B cell-rich tertiary lymphoid structures during antibody-toxin and anti-CD40 combination therapy in glioblastoma

2026-04-17

Abstract excerpt

<title>Abstract</title> <p>Glioblastoma (GBM) is characterized by aberrant neovascularization and angiogenesis. Bevacizumab (Avastin), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is clinically used with chemotherapy for patients with GBM, yet its impact on the tumor immune microenvironment remains poorly understood. Transcriptomic profiling of matched pre- and post-treatment tumors...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ff7331e3-1145-5db5-b031-d055bfcb447a
DOI
10.21203/rs.3.rs-9350019/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Anti-VEGF vascular remodeling drives germinal center B cell-rich tertiary lymphoid structures during antibody-toxin and anti-CD40 combination therapy in glioblastomaDOI 10.21203/rs.3.rs-9350019/v1
Select a neighboring publication to make it the new centre.